NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit

BENSALEM, Pa., May 24, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI).

Class Period: February 24, 2022February 28, 2024

Lead Plaintiff Deadline: July 12, 2024

Investors suffering losses on their Inari investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 215-638-4847 or by email to [email protected].

The complaint filed alleges that, throughout the Class Period, Defendants: (1) repeatedly touted Inari’s financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

[email protected]

www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith


Go to Source